Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Palisade Bio (PALI) EBITDA Margin (2016 - 2025)

Palisade Bio (PALI) has disclosed EBITDA Margin for 14 consecutive years, with 58440.0% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin changed N/A to 58440.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 143212.5%, a N/A change, with the full-year FY2023 number at 5228.0%, changed N/A from a year prior.
  • EBITDA Margin was 58440.0% for Q3 2025 at Palisade Bio, down from 142150.0% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 231000.0% in Q1 2025 to a low of 1011.6% in Q1 2023.
  • A 3-year average of 86142.41% and a median of 58440.0% in 2025 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 12598384bps in 2021; the steepest drop was 12598384bps in 2021.
  • Palisade Bio's EBITDA Margin stood at 133.67% in 2021, then crashed by -857bps to 1011.6% in 2023, then skyrocketed by 5877bps to 58440.0% in 2025.
  • Per Business Quant, the three most recent readings for PALI's EBITDA Margin are 58440.0% (Q3 2025), 142150.0% (Q2 2025), and 231000.0% (Q1 2025).